Skip to content
Open access

Pathogenic KCNQ5 variant in a patient with severe epilepsy and neurodevelopmental disorder: a case report with neuromodulatio

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: Patient B.V.T.T., male, 12 years old, with autism spectrum disorder, neurodevelopmental delay, and epilepsy onset at 4 years and 2 months of age. From the beginning, he presented photosensitivity and absence seizures, later progressing to frequent generalized tonic-clonic seizures, with an average of eight episodes per day and peaks of up to 14 seizures in a single day, remaining clinically refractory despite the combined use of multiple antiseizure medications. On longitudinal examination, psychomotor agitation, temporospatial disorientation, ataxic gait, absence of speech in complete sentences, and lack of literacy were observed. In the etiological investigation, karyotype and testing for fragile X syndrome showed no abnormalities. Exome sequencing identified a rare pathogenic variant in the KCNQ5 c.1106C>A (p.Pro369Gln), ENST00000355194, the only variant described worldwide to date,located on chromosome 6, related to the regulation of neuronal potassium channels. Given the pharmacoresistance, the patient underwent deep brain stimulation with implantation of Deep Brain Stimulation (DBS) in September 2025. After progressive adjustments of the stimulation parameters, an approximate 30% to 40% reduction in seizure frequency was observed, with an increase in the interval between episodes to eight to ten days, although sporadic seizures associated with absence seizures persist. Discussion: KCNQ5 encodes the Kv7.5 subunit of the voltage-gated potassium channels of the Kv7 family, responsible for the neuronal M-current, which is important for stabilizing the membrane potential and limiting neuronal excitability. Alterations in these channels may impair this control and favor genetic epilepsies and neurodevelopmental disorders. Pathogenic variants in KCNQ5 have been mainly associated with global developmental delay, intellectual disability, and epilepsy. Studies have also expanded this spectrum to developmental epileptic encephalopathy and genetic generalized epilepsies, reinforcing the role of this gene in the regulation of cerebral excitability. As this association has been recognized only recently, the number of reported cases remains small. In addition, the variants may cause loss of function, gain of function, or dominant-negative effect, which may explain the clinical heterogeneity and diagnostic difficulty. In this context, the description of new cases is important to broaden the phenotypic spectrum of KCNQ5, clarify its pathophysiological mechanisms, and reinforce the relevance of genetic investigation in patients with epilepsy and neurodevelopmental disorders Final Comments: This report reinforces the role of KCNQ5 as a rare cause of epilepsy associated with neurodevelopmental disorders and highlights the importance of exome sequencing in cases of pharmacoresistant epilepsy. The partial reduction in seizures after deep brain stimulation suggests a potential benefit of neuromodulation as an adjuvant therapeutic strategy in selected patient.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.